Potassium-competitive acid blockers (PCABs) constitute an emerging class of drugs for the treatment of acid-related disorders. They represent an alternative to proton pump inhibitors (PPIs), which have been the standard therapy but present certain limitations. Currently, PCABs are available in Latin America and offer a promising therapeutic option. This review compares both drug classes across various key aspects. Potassium-competitive acid blockers (PCABs) offer significant advantages over proton pump inhibitors (PPIs) in terms of speed of action, potency, and duration of acid suppression, as well as efficacy in the treatment of erosive esophagitis and Helicobacter pylori eradication, among other aspects. Additionally, they exhibit lower interindividual variability. Currently, PCABs are available in Latin America and represent a promising therapeutic option. This review compares both dr...

Helicobacter pylori (H. pylori) is the primary etiological agent of gastric adenocarcinoma, which affects over 60% of the global population, with a significant prevalence in Latin America. Given its impact on the affected population, it is crucial to understand the diagnostic tools available for detecting this infection. While clarithromycin-based therapies are still widely used, the high rates of resistance to this antibiotic in the region needs the establishment of alternative, more effective treatments as the standard of care, such as bismuth-based quadruple therapy or high-dose dual therapy with amoxicillin. In cases of refractory infection, local data registries are valuable for informed decision-making.